Alastair is a founder of Avacta and has been responsible for the leading the management, strategic development and fund raising for the company since IPO in 2006.
He has a degree and PhD in Physics from Manchester University and, after working in the US for a period, took up a position at Leeds University in 1995. At the age of 38 he was awarded the Chair of Molecular Biophysics and grew, over ten years, one of the leading biophysics research groups in Europe. He left his academic career in 2007 to focus full time on delivering value to Avacta shareholders.
Alastair’s deep scientific and technical knowledge combined with a highly commercial mindset enabled him to identify the opportunity presented by the Affimer technology, an engineered alternative to antibodies for diagnostics and therapeutics. Avacta acquired the intellectual property underpinning Affimer technology in 2012. Alastair has delivered on this change in strategy for the Group and Avacta is now commercialising Affimer reagents via a licensing model and building a pipeline of best-in-class and first-in-class Affimer therapeutics. The company has sites in Wetherby and Cambridge and employs around 80 people.